Pancreatic adenocarcinoma third line systemic treatments: a retrospective cohort study.

ABSTRACT:

Background

Chemotherapy for metastatic pancreatic adenocarcinoma (PDAC) primarily relies on FOLFIRINOX (LV5FU- irinotecan - Oxaliplatine) and Gemcitabine - Nab-Paclitaxel in the first-line setting. However, second-lines remain less well-defined and there is limited data regarding third-line treatments. The objective of our study was to determine the proportion of patients advancing to third line chemotherapy, to outline the various third-line chemotherapy regimens used in routine practice and to evaluate their respective efficacy.

Methods

A retrospective single-center cohort from 2010-2022 compiled baseline characteristics, treatment outcomes and survival of PDAC patients who received at least one chemotherapy line in a French tertiary-center. Overall survivals (OS) were ana

SUBMITTER: Gueiderikh A 

PROVIDER: S-EPMC10898186 | biostudies-literature | 2024 Feb

REPOSITORIES: biostudies-literature